Second safety interim analysis report to DSMB
April 09, 2020 - The DMSB chaired by prof Michael Hill from Calgary has evaluated our report on the first 31 cases included in DUMAS and identified no safety concerns, and recommended that the study continued as planned.
First safety interim analysis report to DSMB
February 02, 2020 - First safety interim analysis report to DSMB: no safety concerns.
February 05, 2020 - We are also registered under NCT04256473 ( https://clinicaltrials.gov/ct2/show/NCT04256473)
December 04, 2019 – We are registered under NL7409 (NTR7634) ( https://www.trialregister.nl/trial/7409). The NTR is part of the World Health Organization (WHO) International Clinical Trial Registry Platform (http://apps.who.int/trialsearch/), where DUMAS can be found as well (http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NTR7634).
May 17, 2019 – IRB approval
Aug 10, 2019 – First patient included in the trial in the Erasmus MC, Rotterdam